Promise of AI in MS Research and Treatment Showcased at ACTRIMS 2024
March 3rd 2024The poster session at the Americas Committee for Research and Treatment in Multiple Sclerosis (ACTRIMS) Forum 2024 dedicated a section to emerging developments in the use of artificial intelligence (AI) in research and treatment approaches in multiple sclerosis (MS).
Read More
Highlighting Progress, Addressing Unmet Needs in MS Rehabilitation Trials
March 3rd 2024Speakers on the final day of the Americas Committee for Research and Treatment in Multiple Sclerosis (ACTRIMS) Forum 2024 discussed advancements in rehabilitation trials in multiple sclerosis (MS) and unmet research needs.
Read More
Imaging and 3D Modeling a Key Focus at ACTRIMS 2024
March 2nd 2024On day 2 of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024, speakers gave great attention to novel developments in the field of imaging and 3D modeling in multiple sclerosis (MS).
Read More
Spotlighting Efforts to Improve Care Equity, Research Access in MS
March 1st 2024Speakers at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024 focused their attention on avenues to improve research accessibility for investigators and care access for patients with multiple sclerosis (MS).
Read More
Advancing the Clinical Understanding of MS: Emerging Concepts Presented at ACTRIMS 2024
March 1st 2024The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 opened with discussions on the novel concepts emerging in multiple sclerosis (MS) research, such as the associations between synaptic loss and hypoxia with disease progression.
Read More
Children With SCD Exhibit Distinctive Palatal Rugae Patterns
February 29th 2024A cross-sectional study analyzing morphological and dimensional features of palatal rugae patters revealed that distinct anomalies exist in children with sickle cell disease (SCD) compared with children without.
Read More
ACTRIMS 2024 Seeks to Explore and Break Barriers in MS
February 26th 2024The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) will host its ninth annual meeting in West Palm Beach, Florida, from February 29 to March 2, 2024, to address a plethora of barriers faced by patients and clinicians managing multiple sclerosis (MS).
Read More
The Promise of Frexalimab in MS Treatment: Part 1
February 26th 2024Patrick Vermersch, MD, PhD, joined The American Journal of Managed Care® for an interview on promising data from a phase 2 clinical trial on frexalimab in the treatment of multiple sclerosis (MS) and associated neurodegeneration.
Read More
Hearing Impairment Disproportionately Affects Patients With SCD, Further Studies Required
February 9th 2024A cross-sectional comparative study demonstrated the increased prevalence of hearing impairment in children and adults with sickle cell disease (SCD) or sickle cell traits compared with healthy individuals.
Read More
Choroid Plexus Indicated in MS Pathology
February 9th 2024A longitudinal, observational study found that the choroid plexus, a network of blood vessels in each ventricle of the brain, plays a potential role in the neurodegenerative and chronic inflammatory process experienced by patients with relapsing remitting multiple sclerosis (MS).
Read More
COVID-19 Vaccination Rates Far Lower in Patients With SCD Compared With General Population
February 4th 2024A state-wide analysis draws attention to the fact individuals with sickle cell disease (SCD) completed a vaccination against COVID-19 at nearly half the rate of individuals without SCD.
Read More
Hospitalization, ER, and Medication Discontinuation Rates Still High in PNH
February 2nd 2024A retrospective analysis surveys the treatment landscape and patterns of patients with paroxysmal nocturnal hemoglobinuria (PNH), illuminating high hospitalization rates and emergency department use despite the availability of multiple treatment options.
Read More
Evidence Linking Sleep to Improved Lower Back Pain Outcomes Is Weak, More Studies Needed
February 2nd 2024A systematic review of randomized controlled trials and prospective cohort studies concludes that sleep could be a prognostic component of lower back pain, but better evidence is needed.
Read More